Many eye diseases begin to appear with age, and millions of people around the world face this chronic condition. They can cause visual impairment and, in some cases, irreversible blindness. Targeting the retina with drugs remains a challenge due to difficulties in drug distribution, crossing the eye barrier, and reaching intraocular tissues at effective therapeutic concentrations.Although intravitreal injections deliver drugs directly to the back of the eye, they are still an invasive technique and can cause a variety of side effects.Conventional preparations such as emulsions, suspensions, or ointments are associated with frequent infusion and inability to reach intraocular tissues.New drug delivery systems and medical equipment have also been designed. However, these treatments are not always effective and sometimes a specialist is required to be present to administer the drugs.Therefore, treatment of age-related eye disorders remains one of the major unmet clinical needs for the management of these broad eye disorders. Nanotechnology may be an appropriate tool for developing effective and non-invasive therapies suitable for self-management. In this review, emerging treatment options for nanoengineering based on cyclodextrin nanocarriers, such as complex aggregates, polyrotaxanes, and hydrogels as inserts, are discussed for the treatment of age-related eye diseases, including their pathophysiology, pharmacological options, and the feasibility of clinical transformation.